The list price of the petitioned anti-cancer drug Enhertu was reportedly set at KRW 1.4 million per vial. This is significantly cheaper than the non-reimbursed price of KRW 2.3 million.

In addition, the National Health Insurance Service (NHIS) will apply a risk-sharing agreement (RSA) system for the reimbursement of the drug, so the actual price of the drug is expected to be lower.

According to industry sources on the 21st, Enhertu’s price is going to be set at an upper limit of about KRW 1.4 million per vial.

The price had been reportedly applied to the drug when it passed HIRA’s Drug Reimbursement Evaluation Committee review in February.

In other words,